Moderna on Thursday said it intends to dose some 3,000 adolescent participants in the U.S. ages 12 to less than 18 years with either a placebo or a 100 μg dose.
“Our goal is to generate data in the spring of 2021 that will support the use of mRNA-1273 in adolescents in advance of the 2021 school year,” Moderna said in a statement.
Researchers studying the virus have noted that morbidity and mortality associated with Covid-19 infections have been significantly lower in young children and adolescents, though reports of Covid-19 symptoms and deaths have been recorded.
As of October, the American Academy of Pediatrics reported that nearly 700 000 child and adolescent Covid-19 cases had been reported in the U.S., roughly 10.7% of all cases, with more than 5,000 cumulative hospitalizations and more than 100 deaths.
The trial expansion comes as Pfizer's (PFE) - Get Report Covid-19 vaccine receives a final review from a Food and Drug Administration advisory committee that could authorize the first coronavirus vaccine in the U.S.